FibroBiologics, Inc. (FBLG)
| Market Cap | 6.96M -60.4% |
| Revenue (ttm) | n/a |
| Net Income | -18.14M |
| EPS | -4.77 |
| Shares Out | 6.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 156,199 |
| Open | 0.960 |
| Previous Close | 0.950 |
| Day's Range | 0.960 - 1.050 |
| 52-Week Range | 0.620 - 9.654 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 12.50 (+1,150.0%) |
| Est. Earnings | Oct 30, 2026 |
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, includi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for FBLG stock is "Buy." The 12-month stock price target is $12.5, which is an increase of 1,150.00% from the latest price.
News
FibroBiologics’ patent application accepted in Australia
FibroBiologics (FBLG) announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled “Cellular Blend for the Regeneration of Chondrocytes or Car...
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated...
FibroBiologics files U.S. patent application covering, GLP-1, other peptides
FibroBiologics (FBLG) announced that it has filed a U.S. patent application covering a new cell-based technology designed to continuously produce peptides such as GLP-1, GIP and GLP-2 inside the body.
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 27...
FibroBiologics announces grant of European patent
FibroBiologics (FBLG) announced that the European Patent Office has granted European Patent No. 3568465, titled “Methods of Enhancing Fibroblast Therapeutic Activity.” The patent covers methods of aug...
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration H...
FibroBiologics Transcript: Investor update
A differentiated fibroblast cell therapy platform is advancing with lead programs in diabetic foot ulcers and psoriasis, supported by strong IP and a robust pipeline. Interim clinical data for wound care is expected before year-end, with financial resources and strategic partnerships positioned to support growth.
FibroBiologics Transcript: EGM 2026
Shareholders approved the issuance of new shares related to outstanding warrants. Updates included clinical progress in wound care and psoriasis, new board appointments, and a robust pipeline targeting chronic diseases. No questions were raised during the meeting.
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focu...
FibroBiologics Slides: Corporate presentation
FibroBiologics has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on September 9, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics announces USPTO issued patent on use of fibroblasts
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,721,866, titled “Therapeutic Use of Fibroblasts for Use in Wound Healing.” The ...
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- Fibro...
FibroBiologics announces USPTO issued patent for Fibroblast Conditioned Media
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,716,055, titled “Treatment of Disc Degenerative Disease and Stimulation of Prot...
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("Fibr...
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus...
FibroBiologics Regains Compliance with Nasdaq Trading Rules
HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus...
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), ...
FibroBiologics says Australian patent accepted for Cannabidiol Adjuvant Therapy
FibroBiologics (FBLG) announced the acceptance by IP Australia of Australian Patent Application No. 2020368344, entitled “Cannabidiol Adjuvant Therapy for Treatment of Disc Degenerative Disease.” The ...
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat degenerative disc disease HOUSTON, Aug. 20, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("F...
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroids HOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"...
FibroBiologics awarded new patent from USPTO
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,691,147, entitled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibr...
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiol...
FibroBiologics announces EPO granted patent for gene cartilage therapy
FibroBiologics (FBLG) announced that the European Patent Office, or EPO, has granted the Company’s patent entitled “Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells.” The gran...
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathways HOUSTON, Aug. 5, 2026 /PRNewswire/ -- Fibr...